| Code | 8597D | ||||||||||
| MA number | 68/0241/21-S | ||||||||||
| Product Form: | sus ijp 1x100 mg (striek.inj.napln.+2x ihla) | ||||||||||
| MA Status: | D - Marketing Authorisation valid for an unlimited period | ||||||||||
| Type of procedure: | Mutual recognition procedure | ||||||||||
| MAH, country: | TEVA Pharmaceuticals Slovakia s.r.o., Slovakia | ||||||||||
| Therapeutic Class: | 68 - ANTIPSYCHOTICA (NEUROLEPTICA) | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 24 | ||||||||||
| Container: | pre-filled syringe | ||||||||||
| Route of admin.: | Intramuscular use |
| Prescription Status: | Medicinal product subject to medical prescription. |
| Legal basis: | Article 10(1) generic application |
| MA issued: | 21.09.2021 |
| SPC: |
SPC_Paliperidón Teva_01_2022.pdf
|
| PIL: |
PIL_Paliperidón Teva_09_2023.pdf
|
| SPC: |
SPC_Paliperidón Teva_02_2024.pdf
|
| Safety feature | Yes |
| Data update: | 28.02.2024 |
